Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | LVTX |
---|---|---|
09:39 ET | 5000 | 1.8701 |
09:41 ET | 339 | 1.8706 |
09:43 ET | 13402 | 1.96 |
09:45 ET | 300 | 2.01 |
09:48 ET | 4900 | 1.96 |
09:50 ET | 18235 | 1.96 |
09:54 ET | 5800 | 2.04 |
09:56 ET | 3400 | 1.98 |
10:08 ET | 150 | 1.94 |
10:30 ET | 600 | 1.9299 |
10:32 ET | 1139 | 1.945 |
10:35 ET | 100 | 1.94 |
10:39 ET | 200 | 1.96 |
10:42 ET | 1300 | 1.94 |
10:46 ET | 100 | 1.94 |
10:50 ET | 200 | 1.94 |
10:55 ET | 450 | 1.94 |
11:00 ET | 3015 | 1.93 |
11:09 ET | 200 | 1.96 |
11:15 ET | 100 | 1.96 |
11:20 ET | 200 | 1.96 |
11:26 ET | 100 | 1.96 |
11:29 ET | 800 | 1.95 |
11:33 ET | 3000 | 1.9363 |
11:36 ET | 100 | 1.95 |
11:40 ET | 415 | 1.95 |
11:42 ET | 200 | 1.95 |
11:45 ET | 100 | 1.95 |
11:49 ET | 700 | 1.94 |
11:54 ET | 400 | 1.94 |
11:56 ET | 5000 | 1.98 |
11:58 ET | 800 | 1.96 |
12:00 ET | 2199 | 1.979 |
12:07 ET | 3890 | 1.97 |
12:09 ET | 600 | 2.02 |
12:12 ET | 919 | 2.05 |
12:14 ET | 100 | 2.11 |
12:16 ET | 4500 | 2.05 |
12:18 ET | 7081 | 2.07 |
12:20 ET | 2046 | 2.0065 |
12:21 ET | 400 | 2 |
12:25 ET | 112 | 1.9901 |
01:03 ET | 1200 | 2.02 |
01:08 ET | 2304 | 2.03 |
01:32 ET | 2404 | 2.02 |
01:33 ET | 100 | 2.02 |
01:35 ET | 390 | 2.02 |
02:00 ET | 200 | 2.02 |
02:54 ET | 1000 | 1.96 |
02:58 ET | 520 | 1.9792 |
03:00 ET | 610 | 1.97 |
03:12 ET | 897 | 1.98 |
03:16 ET | 500 | 1.97 |
03:48 ET | 1100 | 1.9601 |
03:56 ET | 205 | 1.97 |
03:57 ET | 1000 | 1.9776 |
03:59 ET | 850 | 1.94 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
LAVA Therapeutics NV | 51.0M | -1.8x | --- |
Kezar Life Sciences Inc | 47.8M | -0.5x | --- |
Kronos Bio Inc | 56.8M | -0.5x | --- |
BioLine RX Ltd | 52.8M | -0.8x | --- |
DURECT Corp | 43.8M | -1.6x | --- |
Atara Biotherapeutics Inc | 38.2M | -0.1x | --- |
LAVA Therapeutics NV, formerly known as Lava Therapeutics BV, is a provider of biotechnology research and development services based in the Netherlands. The Company focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $49.2M |
---|---|
Revenue (TTM) | $12.5M |
Shares Outstanding | 26.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.07 |
Book Value | $1.95 |
P/E Ratio | -1.8x |
Price/Sales (TTM) | 3.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -252.58% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.